Compare RMTI & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMTI | BOLD |
|---|---|---|
| Founded | 1994 | 2018 |
| Country | United States | United States |
| Employees | 300 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.9M | 36.5M |
| IPO Year | 2022 | 2024 |
| Metric | RMTI | BOLD |
|---|---|---|
| Price | $0.74 | $1.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $2.00 | ★ $4.00 |
| AVG Volume (30 Days) | ★ 262.8K | 127.7K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $69,258,000.00 | N/A |
| Revenue This Year | $8.64 | N/A |
| Revenue Next Year | $8.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.73 | $0.96 |
| 52 Week High | $2.10 | $1.68 |
| Indicator | RMTI | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 33.55 | 50.05 |
| Support Level | N/A | $1.40 |
| Resistance Level | $1.02 | $1.55 |
| Average True Range (ATR) | 0.04 | 0.08 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 10.07 | 34.15 |
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, acid, and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate, among others. The company delivers the majority of its hemodialysis concentrates products and mixers to dialysis clinics throughout the United States and internationally, utilizing its own delivery trucks and third-party carriers.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.